SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. “We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confident that David and Rita will make a significant impact on SAB BIO,” said Samuel J. Reich, CEO, SAB BIO. Mr. Reich continued, “David is an esteemed biotech executive with a proven track record of growing companies and creating shareholder value, including leading the recent launch of Ohtuvayre®,
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.MarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.MarketBeat
SABS
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form EFFECT
- 1/7/26 - Form 4
- SABS's page on the SEC website